Researchers develop blood test to detect lung cancerAugust 01, 2006Blood test can be used to save lives by identifing lung cancer years earlier than current imaging techniques Lung cancer is the leading cause of cancer death for both men and women in the United States and around the world, mainly because lung cancers are found in late stages and the best treatment opportunities already have been missed. In Kentucky, the incidence of lung cancer is 49 percent higher than the national rate. However, a new blood test being developed at the University of Kentucky could soon change all that. For the past five years, Drs. Edward A. Hirschowitz and Li Zhong have led a team developing the blood test, which could potentially help detect lung cancer in early stages in people with high risk factors for developing the disease. "Early detection of lung cancer is the key to improving survival," said Zhong, who was the lead author of a study appearing in the July issue of the Journal of Thoracic Oncology that described how the test is 90 percent accurate in correctly predicting non-small-cell lung cancer in patients years before any CT scan can detect it. Although the researchers have received almost $1.5 million in funding for the development of the test from various sources, they recently received an additional $175,000 National Institutes of Health grant to transform the blood test into a format that real-world clinicians could easily use. And with further studies confirming the reliability of the new format, it could become the first blood test to predict cancer since the prostate specific antigen (PSA) test was introduced in the 1970s. The multi-biomarker blood test, which works by identifying the body's own immune response to tumors, would help diagnose lung cancer at the earliest stage in those with high risk factors such as age, smoking and genetic history. Globally, lung cancer is by far the biggest cancer killer, with 10 million people diagnosed each year. In the U.S. alone, the number of lung cancer deaths has risen for each of the past five years to nearly 164,000. The main reason for such a high fatality rate is that 85 percent of lung cancers are found in stages too advanced for best treatment opportunities, Zhong said. Half of all patients die within a year of diagnosis. For the next two years, the UK research team will collaborate with the private biotechnology company 20/20 GeneSystems to develop the clinical application for the blood test. "We are hoping in the next several years this test would become available to the public," Zhong said. University of Kentucky |
|||||||||||||||||||||
| Related Lung Cancer Current Events and Lung Cancer News Articles Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Common pain relief medication may encourage cancer growth Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Study raises concerns about outdoor second-hand smoke Indoor smoking bans have forced smokers at bars and restaurants onto outdoor patios, but a new University of Georgia study in collaboration with the Centers for Disease Control and Prevention suggests that these outdoor smoking areas might be creating a new health hazard. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. PET imaging response a prognostic factor after thoracic radiation therapy for lung cancer A rapid decline in metabolic activity on a PET scan after radiation therapy for non-small cell lung cancer is correlated with good local tumor control, according to a study presented by researchers at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting. Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Intervals between lung cancer diagnosis and treatment displays a health care disparity Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||